Heat Biologics Inc. buy melinda
Start price
24.11.18
/
50%
€8.97
Target price
22.01.19
€12.63
Performance (%)
-4.23%
End price
22.01.19
€8.59
Summary
This prediction ended on 22.01.19 with a price of €8.59. With a performance of -4.23%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Heat Biologics Inc. | - | - | - | - |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% | 65.664% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% | 111.170% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% | 55.883% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% | 67.956% |
Comments by melinda for this prediction
In the thread Heat Biologics Inc. diskutieren
SecteurRecherche biotechnologique et médicale
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer.
The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness.
Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.
The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Durham, NC.
Nombre d'employés : 19 personnes.
Stopped prediction by melinda for Heat Biologics Inc.
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€4.61
17.03.20
17.03.20
€21.00
04.11.21
04.11.21
3.99%
05.11.21
05.11.21
Heat Biologics Inc.
Start price
Target price
Perf. (%)
€66.20
13.03.17
13.03.17
€75.77
13.09.17
13.09.17
-44.67%
13.09.17
13.09.17